{"id":"sofosbuvir-velpatasvir-crushed","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, essential for viral replication. Velpatasvir inhibits the NS5A protein, which plays a critical role in HCV replication and assembly. Together, they provide direct-acting antiviral activity against HCV across multiple genotypes.","oneSentence":"Sofosbuvir/velpatasvir is a fixed-dose combination that inhibits hepatitis C virus (HCV) NS5B polymerase and NS5A protein, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:42.866Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, all genotypes"}]},"trialDetails":[{"nctId":"NCT03389061","phase":"PHASE4","title":"Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet","status":"WITHDRAWN","sponsor":"Radboud University Medical Center","startDate":"2018-04-01","conditions":"HCV","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"sofosbuvir/velpatasvir crushed","genericName":"sofosbuvir/velpatasvir crushed","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir/velpatasvir is a fixed-dose combination that inhibits hepatitis C virus (HCV) NS5B polymerase and NS5A protein, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, all genotypes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}